AstraZeneca registers Phase III bladder cancer trial; joins Natera-led breast cancer study
New records show AstraZeneca sponsoring a Phase III adjuvant urothelial cancer trial and collaborating on a French ctDNA-guided breast cancer study.
Two new trial registrations this week involve AstraZeneca, one as lead sponsor and one as collaborator.
- AstraZeneca is sponsoring "TU-04" (NCT07720284), a Phase III trial testing adjuvant Datopotamab Deruxtecan in combination with Rilvegostomig in participants with high-risk muscle invasive urothelial carcinoma1 compared to standard of care. The study is recruiting1 with an estimated enrollment of 915 participants1, and the primary outcome is disease-free survival for Dato-DXd plus rilvegostomig versus standard of care based on investigator assessment1.
- AstraZeneca is a collaborator, not the lead sponsor, on TAILORswitch (NCT07717450), a Phase 3 trial led by UNICANCER2 testing whether switching to camizestrant-abemaciclib combination therapy benefits patients with hormone-dependent metastatic breast cancer whose ctDNA levels rise without other signs of disease progression2. The study is not yet recruiting2, with 370 patients2 planned for the first step.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.